No Data
No Data
Wakamoto Pharmaceutical: Extraordinary Report
Wakamoto Pharmaceutical: Confirmatory letter.
Wakamoto Pharmaceutical: Securities Report - 129th Fiscal Year (April 1, 2023 - March 31, 2024)
Stocks with interesting flavors seen from changes in volume, such as REMIX.
Code Closing price Change Volume <3848>Data application 1000 98 199300 <4937>Waqoo 1795 27 63500 <6190>PXB 513 25 63300 <5035>Housei 499 21 188400 <2525>NZAM 225 40460 520 5131
Wakamoto Pharmaceutical: (Correction/Numerical data correction) Partial correction of the 'March 2024 financial results briefing (Japan standard) (Non-consolidated)'.
Wakamoto Pharmaceutical FY Parent Net Y108.00M Vs Net Y138.00M
Wakamoto Pharmaceutical Co. Ltd. (4512.TO) Japan Year Ended March 31 PARENT 2024 2023 Revenue Y7.74 bln Y8.66 bln Operating Profit (Y1
No Data